Search research articles
Contact Us
Filters
Showing results (61-70 of 113) with videos related to
Page
of 12
Sort By:
Journal of Translational Medicine
|
June 21, 2013
Cellular immunotherapy for refractory hematological malignancies
John L Reagan, Loren D Fast, Howard Safran, et al.
Haematologica
|
August 18, 2025
Strategies for identifying <i>NUP98</i> rearrangements in adult myeloid neoplasms
Lisa D Yuen, Robert P Hasserjian, Amir T Fathi, et al.
Cancer Medicine
|
August 29, 2014
Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study
Eric S Winer, Howard Safran, Boguslawa Karaszewska, et al.
Leukemia & Lymphoma
|
February 15, 2021
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome
Gail J Roboz, Pinkal Desai, Sangmin Lee, et al.
Blood Advances
|
October 17, 2024
Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy
Geoffrey L Uy, Vinod Pullarkat, Praneeth Baratam, et al.
Transfusion
|
July 12, 2021
Peri-transfusion quality-of-life assessment for patients with myelodysplastic syndromes
Gregory A Abel, Heidi D Klepin, Emily S Magnavita, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 9, 2025
Meeting Report From the 2024 Symposium on IRAK4 in Cancer: Highlights and Clinical Updates
Eric S Winer, Marina Konopleva, Han W Tun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 28, 2019
Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)
Frederick Lansigan, Cristiana A Costa, Bassem I Zaki, et al.
NEJM Evidence
|
February 6, 2024
Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia
Jae H Park, Sean Devlin, Benjamin H Durham, et al.
Leukemia & Lymphoma
|
April 28, 2025
Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Rory M Shallis, Julian J Weiss, Eric S Winer, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 113) with videos related to
Sort By:
Page
of 12
Journal of Translational Medicine
|
June 21, 2013
Cellular immunotherapy for refractory hematological malignancies
John L Reagan, Loren D Fast, Howard Safran, et al.
Haematologica
|
August 18, 2025
Strategies for identifying <i>NUP98</i> rearrangements in adult myeloid neoplasms
Lisa D Yuen, Robert P Hasserjian, Amir T Fathi, et al.
Cancer Medicine
|
August 29, 2014
Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study
Eric S Winer, Howard Safran, Boguslawa Karaszewska, et al.
Leukemia & Lymphoma
|
February 15, 2021
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome
Gail J Roboz, Pinkal Desai, Sangmin Lee, et al.
Blood Advances
|
October 17, 2024
Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy
Geoffrey L Uy, Vinod Pullarkat, Praneeth Baratam, et al.
Transfusion
|
July 12, 2021
Peri-transfusion quality-of-life assessment for patients with myelodysplastic syndromes
Gregory A Abel, Heidi D Klepin, Emily S Magnavita, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 9, 2025
Meeting Report From the 2024 Symposium on IRAK4 in Cancer: Highlights and Clinical Updates
Eric S Winer, Marina Konopleva, Han W Tun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 28, 2019
Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)
Frederick Lansigan, Cristiana A Costa, Bassem I Zaki, et al.
NEJM Evidence
|
February 6, 2024
Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia
Jae H Park, Sean Devlin, Benjamin H Durham, et al.
Leukemia & Lymphoma
|
April 28, 2025
Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Rory M Shallis, Julian J Weiss, Eric S Winer, et al.
Page
of 12